115 results about "Dimethyl fumarate" patented technology

The invention provides compositions and methods for treating autoimmune diseases such as multiple sclerosis. The compositions include a combination of an NMDA Receptor antagonist, such as memantine or rimantadine, and a fumarate agent, such as dimethyl fumarate.

Implantable medical devices having anti-restenotic coatings are disclosed. Specifically, implantable medical devices having coatings of certain NF-kappaB inhibitors, particularly certain dialkyl fumarates, are disclosed. Dimethyl fumarate is a particularly preferred dialkyl fumarate. The anti-restenotic medical devices include stents, catheters, micro-particles, probes and vascular grafts. Intravascular stents are preferred medical devices. The medical devices can be coated using any method known in the art including compounding the dialkyl fumarate with a biocompatible polymer prior to applying the coating. Moreover, medical devices composed entirely of biocompatible polymer-dialkyl fumarate blends are disclosed. Additionally, medical devices having a coating comprising at least one dialkyl fumarate in combination with at least one additional therapeutic agent are also disclosed. Furthermore, related methods of using and making the anti-restenotic implantable devices are also disclosed.

Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.

The invention discloses dimethyl fumarate enteric-coated pellets and a preparation method thereof. Each enteric-coated pellet comprises a blank pellet core, an active drug layer wrapping the blank pellet core, an isolating layer, an inner layer enteric-coated coating layer and an outer layer enteric-coated coating layer from inside to outside. The enteric-coated pellets are simple in process, complete in release, good in reproducibility, small in gastrointestinal tract irritation, safe and effective.

The invention relates to a dimethyl fumarate-containing enteric slow-release pellet for treating multiple sclerosis. The dimethyl fumarate-containing enteric slow-release pellet is characterized in that the pellet is subjected to coating, one layer gives play to enteric effect, and one layer gives play to slow-release effect, so that the pellet is controlled to slowly release active substances according to a certain rate after arriving at intestinal tracts.

The invention relates to a mildew-inhibiting composition which comprises the components in parts by weight as follows: 10-15 parts of modified nanometer montmorillonite, 5-10 parts of dimethyl fumarate, 2-5 parts of ethyoxyl quin, 20-25 parts of sodium glutamate, 20-30 parts of nucleotide disodium, 10-15 parts of sanguinarine, 15-30 parts of glutathione, 10-15 parts of choline chloride, 15-20 parts of glycine betaine, 10-15 parts of sodium sorbate, 2-5 parts of chitosan, 3-9 parts of gala mannan oligosaccharide, and 1-5 parts of fructo-oligosaccharide. The mildew-inhibiting composition provided by the invention further has the effects of enhancing the immune function of animals, strengthening the detoxifying function by liver and kidney and promoting the feed intake of poultry besides good bacteria-inhibiting and sterilizing effects.

The invention discloses a continuous production process for dimethyl fumarate. The process comprises the following steps of: uniformly filling a strong acid cation exchange resin catalyst into a reaction cylinder, and heating at the temperature of between 60 and 100 DEG C; adding fumaric acid and a methanol solution which serve as reaction raw materials into the reaction cylinder from an inlet of the fixed reaction cylinder, regulating the flow velocity of a flow pump to ensure that the raw materials are kept in the reaction cylinder for 4 to 8 hours, and collecting a reaction product at an outlet; introducing the reaction product into cold water, stirring, and crystallizing a large number of white crystals; filtering, and washing a filter cake by using 8 to 10 percent Na2CO3; and filtering again, washing the filter cake to be neutral by using distilled water, drying at room temperature, and thus obtaining the dimethyl fumarate. In the process, strong acid cation exchange resin is utilized, does not corrode reaction equipment and pollute the environment, can be repeatedly used and is a good environment-friendly catalyst. The catalyst is fixed in the reaction cylinder; the materials are continuously fed and discharged, so that the continuous operation of the reaction can be realized; and the process has simple reaction conditions and makes the operation convenient.

The invention discloses a method for preparing fumaric dimethyl ester (DMF). The method comprises the steps of taking maleic anhydride as raw material and subjecting the raw material and methanol to catalytic reaction in the presence of a solid-acid SO4/Al2O3 catalyst so as to obtain the fumaric dimethyl ester, namely a target product of the invention. The purity of the fumaric dimethyl ester obtained by the preparation method is up to over 98.5 percent, and the yield of the fumaric dimethyl ester is between 85 and 95 percent. Compared with the prior art, the method has the advantages that the method adopts the solid-acid SO4/Al2O3 catalyst, is safe and convenient in operation, improves environment, reduces corrosion on equipment, can cyclically recycle reaction solvent and the solid-acid catalyst, reduces the three wastes, ensures stable product quality, and is suitable for industrial production.

A dimethyl fumarate (DMF) softgel is composed of the core prepared from DMF particles and the wall layer prepared from refined paraffin wax, animal wax, plant wax, or synthetic high-molecular material. Its advantages are no irritation to people, and high output rate and effect.

The invention discloses high-density dimethyl fumarate enteric-coated granules and a preparation method thereof. The density of the high-density dimethyl fumarate enteric-coated granules is 1.0g/mL or higher, or is 1.3g/mL or higher, or is 1.6g/mL or higher. Preparation size of the high-density dimethyl fumarate enteric-coated granules is small; the high-density dimethyl fumarate enteric-coated granules are convenient for administration, and are especially suitable for patients, elders, and children with swallowing difficulty, and are capable of increasing patient compliance; preparation content uniformity is high; rapid release is realized; stability is high; and the preparation method is simple, and is suitable for industrialized production.

The invention provides a dimethyl fumarate enteric-coated pellet. The dimethyl fumarate enteric-coated pellet comprises a core, an intermediate coating layer and an enteric layer, wherein the coating material of the intermediate coating layer is copovidone; by calculating in percentage by weight with respect to the core, the increased weight of the intermediate coating layer is 4%-40%; the enteric-coated pellet can be further filled with a capsule so as to be prepared into a capsule, or mixed with other auxiliary materials so as to be prepared into a tablet, or mixed with other auxiliary materials so as to be prepared into a suspension. Even the weight of the intermediate coating layer is increased, the medicine in the prepared enteric-coated pellet still can retain a high release rate. The preparation method is simple and feasible, and is suitable for industrial production.

The present invention discloses a special cherry preservative which is composed of the following components (parts by weight): 22 parts of tea leaves, 23 parts of propolis, 22 parts of dried tangerine peels, 9 parts of chitosans, 20 parts of lotus leaves, 4 parts of butylated hydroxy anisole, 6 parts of benzoic acids, 7 parts of propyl gallate, 7 parts of vitamin E, 8 parts of vanilla amide, 11 parts of rosemary, 10 parts of salvia japonica, 9 parts of sorbitols, 10 parts of maltitols, 4 parts of xylitols, 18 parts of sesame oil, 20 parts of rice bran oil, 3 parts of cephalins, 3 parts of polylysines, 3 parts of cinnamic acids, 3 parts of beta-cyclodextrins, 2 parts of sodium diacetate, 2 parts of sorbic acid, 6 parts of glycerol monocaprylate and 5 parts of dimethyl fumarate. The special cherry preservative can effectively reduce adhesive rate of the preservative to achieve lower residues, at the same time the toxicity of the preservative is much lower than the existing commercial products, and thus the preservative is suitable for the need of a large-scale industrial production.

The present invention discloses a special onion preservative which is composed of the following materials (parts by weight): 22 parts of tea leaves, 23 parts of propolis, 22 parts of dried tangerine peels, 19 parts of konjac, 19 parts of forsythia suspensa, 9 parts of chitosans, 20 parts of lotus leaves, 4 parts of butylated hydroxy anisole, 7 parts of vitamin E, 8 parts of vanilla amide, 11 parts of rosemary, 10 parts of salvia japonica, 9 parts of sorbitols, 10 parts of maltitols, 4 parts of xylitols, 18 parts of sesame oil, 20 parts of rice bran oil, 3 parts of cephalins, 3 parts of polylysines, 3 parts of cinnamic acids, 3 parts of beta-cyclodextrins, 2 parts of sodium diacetate, 2 parts of sorbic acid, 6 parts of glycerol monocaprylate and 5 parts of dimethyl fumarate. The special onion preservative can effectively reduce adhesive rate of the preservative to achieve lower residues, at the same time the toxicity of the preservative is much lower than the existing commercial products, and thus the preservative is suitable for the need of a large-scale industrial production.

The invention discloses a special antistaling agent for litchi. The special antistaling agent comprises the following components by weight: 22 parts of tea leaf, 23 parts of propolis, 19 parts of fructus forsythia, 9 parts of chitosan, 20 parts of lotus leaf, 4 parts of butylated hydroxyanisole, 6 parts of benzoic acid, 7 parts of propyl gallate, 7 parts of vitamin E, 8 parts of vanilla amide, 11 parts of rosemary, 10 parts of sage, 9 parts of sorbitol, 10 parts of maltitol, 4 parts of xylitol, 18 parts of sesame oil, 20 parts of rice bran oil, 3 parts of cephalin, 3 parts of polylysine, 3 parts of cinnamic acid, 3 parts of beta-cyclodextrin, 2 parts of sodium diacetate, 2 parts of sorbic acid, 6 parts of mono-caprylin glycerate and 5 parts of dimethyl fumarate. The special antistaling agent for litchi provided by the invention has the beneficial effects of capability of effectively reducing the adhesive rate of the antistaling agent, low residue, much lower toxicity compared with conventional commercial products and capacity of meeting the need of large-scale industrial production.

The invention provides cinnabar coloring paint which is good in adhesion. After a cinnabar painting is colored, the paint can be well attached to the surface of the cinnabar painting and not prone to peeling off. Meanwhile, cured high-aluminum powder, modified nanowhisker materials, dimethyl fumarate, polyurethane resin, polytetrafluoroethylene, zinc stearate, dibutyl phthalate, silicone macromonomer and a white oil component are added. Adhesion of the cinnabar coloring paint is guaranteed, meanwhile, gaps between all colored substances of the cinnabar coloring paint are small, the outer surface of the colored part of the cinnabar painting forms a smooth curved face, and the cinnabar painting looks natural.

The invention discloses a steel derusting/phosphating solution which is prepared from the following raw materials: 80-85 parts of phosphoric acid, 32-35 parts of hydrochloric acid, 12-15 parts of tartaric acid, 8-12 parts of ammonia water, 6-8 parts of carboxylic acid, 5-6 parts of stearic acid, 4-5 parts of ferric oxide, 6-7 parts of aluminum hydroxide, 7-8 parts of zinc powder, 5-6 parts of zinc hydroxide, 2-3 parts of anhydrous cupric sulfate, 5-6 parts of dimethyl fumarate, 3-5 parts of silicon oil, 4-6 parts of formic acid, 5-6 parts of carrageenin, 5-6 parts of glycerol, 3-5 parts of iron powder, 3-6 parts of copperas powder, 5-6 parts of oxalic acid, 3-5 parts of succinic acid, 3-6 parts of thiocarbamide and 3-5 parts of disodium edetate. The steel derusting/phosphating solution has favorable derusting effect, can form an anticorrosive coating on the metal surface, especially can treat the rusty steel surface to remove rust, and forms a smooth and compact phosphate coating on the treated metal surface, thereby achieving the effect of preventing metallic corrosion.

The present invention relates to pharmaceutical compositions containing dimethyl fumarate (DMF), More specifically, the present invention relates to a pharmaceutical composition for oral use in treating hyperproliferative, inflammatory or autoimmune disorders by administering a low daily dosage in the range of 410 mg±5% or 400 mg±5% dimethyl fumarate, wherein the pharmaceutical formulation is in the form of an erosion matrix tablet.

A compound specified by formula (I), in particular dimethylfumarate (trans-1,2-ethylenedicarboxylic acid dimethyl ester) is provided for use in prevention or therapy of gout, acne, pyoderma gangrenosum, Vitiligo, cardiovascular disease, metabolic syndrome, diabetes and/or complications of diabetes. Also provided are a dosage form comprising said compound and a method of treatment comprising administration of said compound to a patient in need thereof.